2025 Q3 -tulosraportti
12 päivää sitten36 min
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
415
Myynti
Määrä
1 298
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 830 | NON | NON | ||
| 320 | NON | AVA | ||
| 93 | NRD | NON | ||
| 123 | NON | NON | ||
| 20 | NON | NON |
Ylin
10,6VWAP
Alin
9,5VaihtoMäärä
1 99 631
VWAP
Ylin
10,6Alin
9,5VaihtoMäärä
1 99 631
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 19.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12. | |
| 2025 Q2 -tulosraportti | 28.8. | |
| 2025 Q1 -tulosraportti | 25.4. | |
| 2024 Q4 -tulosraportti | 27.2. | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Datan lähde: Quartr, FactSet
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·12 t sittenIsn't that good news?
·11 min sittenPrecisely - then it's good to have pulled out all the stops 💥💪
·3 min sittenI only have 4425 shares of which 1400 are in a pension account. I should have 5000 more😂
·21 t sittenStrong move by Curasight with this directed issue. 4.29% dilution = quite modest. Capital until the end of 2026. Motives and use of proceeds: In order to support the clinical development of uTRACE® and uTREAT® and strengthen Curasight's financial position, the Company has chosen to carry out the Directed Issue and enter the Loan Facility. The net proceeds from the Financing are intended to be utilized as follows: The completion of the phase 1 study with uTREAT® (brain cancer). The completion of the phase 2 study with uTRACE® (prostate cancer). The initiation of the phase 3 study with uTRACE® (prostate cancer), together with Curium. Submission of an FDA Investigational New Drug (IND) application for uTREAT® in brain cancer. The Board of Directors assesses that the net proceeds from the Financing will be sufficient to fund the Company's operations to the end of 2026.
·23 t sitten · MuokattuIssuance scenario : large discount (-30 %) Issue price: 9,8 × 0,70 ≈ 6,9 DKK New shares ≈ 15 mio. / 6,9 ≈ 2,17 mio. New price ≈ 449,53 𝑚 + 15,0 𝑚 / 48,04 𝑚 ≈ 9,6 Even with a 50% discount, it will not significantly affect the theoretical price. There should not be any major negative (theoretical) price impact due to the issue, as it is, after all, a very limited amount (15 m) compared to the company's value of approx 450 m. But often a price reaction towards the issue price is seen, but will that happen here, as there are many positive price triggers ahead? As well as the fact that the share is very illiquid (approx. 2 million new shares won't change that. It will be interesting to see who buys the shares, and that the new loan facilities secure ongoing operations into 2H 2026. Definitely positive, and that Ulrich confirms that we will get the results of the PoC'en for uTREAT as planned in Q4 2025. The case is definitely intact and has actually been further strengthened today. Smart to do the issue before the PoC'en results..! Monday will be exciting..!·22 t sitten · MuokattuPossible comparison can be made with cessatech: They carried out a directed share issue on May 28 this year: 28 maj 17:30 - Cessatech announces intention to carry out a directed share issue ahead of U.S. commercial launch. 28 maj 22:30 - Cessatech has carried out a directed share issue of approximately DKK 14.8 million to strengthen its financial position ahead of U.S. commercial launch. The new shares were sold for 12,72kr. On the same day (28. Maj), the closing price was 13,46. Quick, done deal with a relatively modest 6,3% dilution.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
12 päivää sitten36 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·12 t sittenIsn't that good news?·11 min sittenPrecisely - then it's good to have pulled out all the stops 💥💪·3 min sittenI only have 4425 shares of which 1400 are in a pension account. I should have 5000 more😂
- ·21 t sittenStrong move by Curasight with this directed issue. 4.29% dilution = quite modest. Capital until the end of 2026. Motives and use of proceeds: In order to support the clinical development of uTRACE® and uTREAT® and strengthen Curasight's financial position, the Company has chosen to carry out the Directed Issue and enter the Loan Facility. The net proceeds from the Financing are intended to be utilized as follows: The completion of the phase 1 study with uTREAT® (brain cancer). The completion of the phase 2 study with uTRACE® (prostate cancer). The initiation of the phase 3 study with uTRACE® (prostate cancer), together with Curium. Submission of an FDA Investigational New Drug (IND) application for uTREAT® in brain cancer. The Board of Directors assesses that the net proceeds from the Financing will be sufficient to fund the Company's operations to the end of 2026.
- ·23 t sitten · MuokattuIssuance scenario : large discount (-30 %) Issue price: 9,8 × 0,70 ≈ 6,9 DKK New shares ≈ 15 mio. / 6,9 ≈ 2,17 mio. New price ≈ 449,53 𝑚 + 15,0 𝑚 / 48,04 𝑚 ≈ 9,6 Even with a 50% discount, it will not significantly affect the theoretical price. There should not be any major negative (theoretical) price impact due to the issue, as it is, after all, a very limited amount (15 m) compared to the company's value of approx 450 m. But often a price reaction towards the issue price is seen, but will that happen here, as there are many positive price triggers ahead? As well as the fact that the share is very illiquid (approx. 2 million new shares won't change that. It will be interesting to see who buys the shares, and that the new loan facilities secure ongoing operations into 2H 2026. Definitely positive, and that Ulrich confirms that we will get the results of the PoC'en for uTREAT as planned in Q4 2025. The case is definitely intact and has actually been further strengthened today. Smart to do the issue before the PoC'en results..! Monday will be exciting..!·22 t sitten · MuokattuPossible comparison can be made with cessatech: They carried out a directed share issue on May 28 this year: 28 maj 17:30 - Cessatech announces intention to carry out a directed share issue ahead of U.S. commercial launch. 28 maj 22:30 - Cessatech has carried out a directed share issue of approximately DKK 14.8 million to strengthen its financial position ahead of U.S. commercial launch. The new shares were sold for 12,72kr. On the same day (28. Maj), the closing price was 13,46. Quick, done deal with a relatively modest 6,3% dilution.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
415
Myynti
Määrä
1 298
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 830 | NON | NON | ||
| 320 | NON | AVA | ||
| 93 | NRD | NON | ||
| 123 | NON | NON | ||
| 20 | NON | NON |
Ylin
10,6VWAP
Alin
9,5VaihtoMäärä
1 99 631
VWAP
Ylin
10,6Alin
9,5VaihtoMäärä
1 99 631
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 19.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12. | |
| 2025 Q2 -tulosraportti | 28.8. | |
| 2025 Q1 -tulosraportti | 25.4. | |
| 2024 Q4 -tulosraportti | 27.2. | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Datan lähde: Quartr, FactSet
2025 Q3 -tulosraportti
12 päivää sitten36 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 19.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12. | |
| 2025 Q2 -tulosraportti | 28.8. | |
| 2025 Q1 -tulosraportti | 25.4. | |
| 2024 Q4 -tulosraportti | 27.2. | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Datan lähde: Quartr, FactSet
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·12 t sittenIsn't that good news?·11 min sittenPrecisely - then it's good to have pulled out all the stops 💥💪·3 min sittenI only have 4425 shares of which 1400 are in a pension account. I should have 5000 more😂
- ·21 t sittenStrong move by Curasight with this directed issue. 4.29% dilution = quite modest. Capital until the end of 2026. Motives and use of proceeds: In order to support the clinical development of uTRACE® and uTREAT® and strengthen Curasight's financial position, the Company has chosen to carry out the Directed Issue and enter the Loan Facility. The net proceeds from the Financing are intended to be utilized as follows: The completion of the phase 1 study with uTREAT® (brain cancer). The completion of the phase 2 study with uTRACE® (prostate cancer). The initiation of the phase 3 study with uTRACE® (prostate cancer), together with Curium. Submission of an FDA Investigational New Drug (IND) application for uTREAT® in brain cancer. The Board of Directors assesses that the net proceeds from the Financing will be sufficient to fund the Company's operations to the end of 2026.
- ·23 t sitten · MuokattuIssuance scenario : large discount (-30 %) Issue price: 9,8 × 0,70 ≈ 6,9 DKK New shares ≈ 15 mio. / 6,9 ≈ 2,17 mio. New price ≈ 449,53 𝑚 + 15,0 𝑚 / 48,04 𝑚 ≈ 9,6 Even with a 50% discount, it will not significantly affect the theoretical price. There should not be any major negative (theoretical) price impact due to the issue, as it is, after all, a very limited amount (15 m) compared to the company's value of approx 450 m. But often a price reaction towards the issue price is seen, but will that happen here, as there are many positive price triggers ahead? As well as the fact that the share is very illiquid (approx. 2 million new shares won't change that. It will be interesting to see who buys the shares, and that the new loan facilities secure ongoing operations into 2H 2026. Definitely positive, and that Ulrich confirms that we will get the results of the PoC'en for uTREAT as planned in Q4 2025. The case is definitely intact and has actually been further strengthened today. Smart to do the issue before the PoC'en results..! Monday will be exciting..!·22 t sitten · MuokattuPossible comparison can be made with cessatech: They carried out a directed share issue on May 28 this year: 28 maj 17:30 - Cessatech announces intention to carry out a directed share issue ahead of U.S. commercial launch. 28 maj 22:30 - Cessatech has carried out a directed share issue of approximately DKK 14.8 million to strengthen its financial position ahead of U.S. commercial launch. The new shares were sold for 12,72kr. On the same day (28. Maj), the closing price was 13,46. Quick, done deal with a relatively modest 6,3% dilution.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
415
Myynti
Määrä
1 298
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 830 | NON | NON | ||
| 320 | NON | AVA | ||
| 93 | NRD | NON | ||
| 123 | NON | NON | ||
| 20 | NON | NON |
Ylin
10,6VWAP
Alin
9,5VaihtoMäärä
1 99 631
VWAP
Ylin
10,6Alin
9,5VaihtoMäärä
1 99 631
Välittäjätilasto
Dataa ei löytynyt